CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞靶向实体瘤的障碍与机遇
英文原题：Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors.
查看英文原题
Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已改变B细胞系血液系统恶性肿瘤的治疗。但要在实体瘤中实现相同疗效，目前仍处于早期探索阶段。本综述总结该领域为有效治疗人类癌症所需克服的挑战，包括肿瘤异质性、真正肿瘤特异性靶点不足、实体瘤病灶中的免疫抑制及代谢限制，以及T细胞迁移缺陷。多个独立团队正在研究所有这些障碍，并在部分情况下尝试靶向克服。随着针对多种人类恶性肿瘤的临床干预开展及不同平台加速进入临床开发，未来几年将出现多种细胞疗法，包括CAR-T，并逐渐成为消除目前无法治愈疾病的常规治疗方式，如某些血液系统恶性肿瘤治疗中已发生的情况。
展开英文摘要原文
CAR T-cell therapy has transformed the treatment of hematological malignancies of the B cell lineage.
However, the quest to fulfil the same promise for solid tumors is still in its infancy. This review summarizes some of the challenges that the field is trying to overcome for effective treatment of human carcinomas, including tumor heterogeneity, the paucity of truly tumor-specific targets, immunosuppression and metabolic restrictions at solid tumor beds, and defective T-cell trafficking.
All these barriers are being currently investigated and, in some cases, targeted, by multiple independent groups. With clinical interventions against multiple human malignancies and different platforms under accelerated clinical development, the next few years will see an array of cellular therapies, including CAR T-cells, progressively becoming routine interventions to eliminate currently incurable diseases, as it happened with some hematological malignancies.
论文信息
- 作者
- Conejo-Garcia JR、Guevara-Patino JA
- 第一作者单位
- Department of Immunology, Gynecologic Oncology and Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.United States
- 通讯作者单位
- b Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.United States
- 文献类型
- 综述
- 期刊
- Immunological investigations2022 Nov
- 原文标识
- PubMed 35797428 · DOI 10.1080/08820139.2022.2096463
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →